AstraZeneca PLC (AZN), along with pharmaceutical company Daiichi Sankyo, Monday announced that fam-trastuzumab deruxtecan-nxki, sold under the brand name ENHERTU, has been granted the Food and Drug Administration's Breakthrough Therapy Designation in the U.S. for adult patients.
The drug is used to treat HER2-positive early breast cancer with residual invasive disease in the breast and/or axillary lymph nodes after neoadjuvant treatment and high risk of disease recurrence.
The designation is supported by data from the DESTINY-Breast05 Phase III trial, which demonstrated that ENHERTU may help halt invasive disease recurrence over the current standard of care.
In the pre-market hours, AZN is trading at $91.38, up 0.07 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Health News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.